Replies to post #286939 on Avid Bioservices Inc (CDMO)

[Protector]

north40K, possibly PPHM not, neither MSK on this topic which with Wolchok's lab are the Melanoma Top-Dogs, IMO.

Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12).

your source

But if the above works then the upcoming clinical trial below will do wonders.

Ranee Mehra, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, "Phase II Study of Pembrolizumab and Bavituximab for Progressive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck"

source

Bavituximab doesn't only suppress IL-10 and TGF-Beta but also stimulates secretion of IL-12 and TNF-Alpha by the MDSC's and Macrophages.

So in combination with bavituximab Pembrolizumab (or for this board the better known Merck trade name KeyTruda, Merck's LEAD IO drug) this should even work better.

After Memorial Sloan Kettering's (Wolchok) acknowledgement that PS-targeting, based in test results, shows to be a beneficial factor in conditioning the tumour environment for other IO treatments (KeyTruda, Opdivo, Yervoy, Durvalumab, etc) I think some melanoma or possibly an Astra Zeneca Durvalumab+Bavituximab in ALL solid cancers could be upcoming (speculation). A broad scope PHASE I does make sense.